My Next Health Inc.

Leading genetics scientist whose research has been shortlisted for a Nobel Prize in Medicine has developed groundbreaking genetics platform for finding root causes of most chronic diseases. Have developed with IBM a digital therapeutics platform for COVID-19 and other infectious diseases as well as chronic pain management.

My Next Health (MNH) is a recently incorporated Delaware corporation that is 80 percent owned by the technology fund Green Sky Labs and the research and development firm The DNA Company. MNH will have the rights to use the genetics platform developed by Dr. Mansoor Mohammed from The DNA Company for application in the areas of drug development and digital therapeutics for chronic pain and infectious diseases. MNH has already received a term sheet from a global hedge fund for $150M upon the company listing on the Nasdaq exchange.

The genetics platform will target the global healthcare market which expected to grow to nearly $12 trillion by 2022. Factors that will drive growth in this market are economic growth, technological developments and the increasing prevalence of diseases due to rising busy and sedentary lifestyles. Factors that could hinder the growth of this market in the future are rising interest rates, increasing awareness of alternative therapies and natural remedies, government provisions in healthcare services, and stringent government regulations.

North America is currently the largest market for healthcare, accounting for 40% of the global market, followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest growing regions in the healthcare market will be the Asia Pacific and Africa followed by the Middle East and South America.

Based on 10,000 case studies conducted by one of the world's leading geneticists, a new approach has been developed to diagnose and provide therapeutics for many chronic diseases. The current mainstream approach to medicine does not factor in the complex relatiionship between genetic systems and the human environment in finding the root causes of many of the health issues facing society. MNH's platform is based on the first comprehensive set of case studies using the lastest genetics research. This has lead to some groundbreaking discoveries in the root causes of a number of cancers, autism, diabetes, cardiovascular diseases, etc.

My Next Health business model includes the following:
1) Clinical trials on cancers, hypertension, autism and cardiovascular disease; 2) Repositioning drugs from failed clinical trials;
3) Digital therapeutics platforms with IBM Watson for chronic pain and infectious diseases.

Health care systems, patients and insurance companies will all benefit from these business lines as the company will have unique diagnostics and therapeutics

For the genetics based clincal trials, 23andMe is the main competitor at a global scale. There are much smaller genetics company that are conducting clincal trials.

Unique proprietary genetics analytics provides more efficient and cost effective methods of discovering new drugs and improving existing clinical trials.

Immediate sales of the genetics/IBM platform are expected to reach $50M in the first year followed by solid growth over the first five years.

Pharmaceutical related sales include licensing or selling the therapeutics developed.

Business model includes conducting clinical trials, repositioning of drugs from failed clinical trials and clinical therapeutics.

Expenditures include:
Working capital
Buiness development
Research and development

One year convertible debentiure
Converts to equity at 25 percent discount to public listing round
Full warrant for 5 years at public listing round price

Clincial trials traditionally have large failure rates and their is always risk of trials not working out.